藥物濫用多合一檢測試劑盒

廣州健侖生物科技有限公司

廣州健侖生物科技有限公司是集研制開發(fā)、銷售、服務(wù)于一體的優(yōu)良企業(yè),公司產(chǎn)品涉及臨床快速診斷試劑、食品安全檢測試劑，違禁品快速檢測，動物疾病防疫檢測試劑，免疫診斷試劑、臨床血液學(xué)和體液學(xué)檢驗試劑、微生物檢驗試劑、分子生物學(xué)檢驗試劑、臨床生化試劑、有機(jī)試劑等眾多領(lǐng)域，同時核心代理Panbio、FOCUS、Qiagen、IBL、CORTEZ、Fuller、Inbios、BinaxNOW、LumuQuick、日本富士、日本生研等多家有名診斷產(chǎn)品集團(tuán)公司產(chǎn)品，致力于為商檢單位、疾病預(yù)防控制中心、海關(guān)出入境檢疫局、衛(wèi)生防疫單位,緝毒系統(tǒng)，戒毒中心，檢驗檢疫單位、生化企業(yè)、科研院所、醫(yī)療機(jī)構(gòu)等機(jī)構(gòu)與行業(yè)提供*、高品質(zhì)的產(chǎn)品服務(wù)。此外，本公司還開展食品、衛(wèi)生、環(huán)境、藥品等多方面的第三方檢測服務(wù)。

廣州健侖生物長期供應(yīng)各種違禁品檢測試紙、違禁品檢測卡、違禁品檢測試劑盒、藥篩試紙、藥篩試劑盒、嗎啡檢測試劑盒、巴比妥檢測試劑盒等。

使用說明書

【產(chǎn)品名稱】

通用名稱：藥物濫用多合一檢測試劑盒

英文名稱：Diagnostic Kit for Nicotine（Colloidal Gold）

【包裝規(guī)格】 

1人份/袋、40人份/盒

Multi DOA Screen Panel are rapid chromatographic immunoassays for the qualitative and simultaneous detection of one to fourteen of the following drugs in a variety of combinations in human urine. The designed cutoff concentrations and direct calibrator for these drugs are as follows:

The test is used to obtain visual qualitative result and is intended for health care professionals use including professionals at point of care sites to assist in the determination of drug compliance. It is not intended for over the counter sale to non-professionals.

This assay provided only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/ Mass Spectrometry (GC/MS) or Liquid Chromatography/ Mass Spectrometry (LC/MS) are the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

本品采用競爭抑制法和膠體金免疫層析技術(shù)，用于定性檢測人體尿液中尼古丁，適用于尼古丁藥物濫用的初步篩查。

主營品牌：美國NovaBios、美國Cortez、國產(chǎn)創(chuàng)侖等等。

主要用途：篩查違禁品濫用殘留、麻醉藥殘留、興奮藥物殘留等等。

檢測范圍：嗎啡、KET、mamp、MDMA、BZO、THC、巴比妥、MTD、BAR、MDMA、AMP、BUP、PCP、TCA、OXY、MET等等。

產(chǎn)品特點：可以根據(jù)需求自主訂制多聯(lián)卡。多聯(lián)卡自由組合，從二聯(lián)到十五聯(lián)都可以訂制。

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

如需訂購或者了解請以下或

mob： 楊   ： 

美國NOVABIOS多聯(lián)檢測杯簡介：

美國NOVABIOS單卡產(chǎn)品簡介：

w the test device, urine specimen, and/or controls to reach room temperature (15-30oC) prior to t

更多產(chǎn)品說明可通過下方的進(jìn)行了解

添加掃一掃二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【 市場部 】       楊永漢
【】 
【騰訊  】
【公司地址】 廣州市清華科技園健新基地番禺石樓鎮(zhèn)健啟路63號二期2幢101-103室

但輕度腫大有時  可能為其功能 升高的表現(xiàn)，較明顯的腫脹則恒為細(xì)胞受損的表現(xiàn)  。但只要損傷 不過重、損傷因子的作用不過長，腫脹仍可恢復(fù)。  線粒體的增大 有時是器官功能負(fù)荷增加引起的適應(yīng)性肥大，此時  線粒體的數(shù)量 也常增多，例如見于器官肥大時。反之，器官萎縮  時，線粒體則 縮小、變少。結(jié)構(gòu)的改變線粒體嵴是能量代謝的明  顯指征，但嵴 的增多未必均伴有呼吸鏈酶的增加。嵴的膜和酶平  行增多反映細(xì) 胞的功能負(fù)荷加重，為一種適應(yīng)狀態(tài)的表現(xiàn)；反之  ，如嵴的膜和 酶的增多不相平行，則是胞漿適應(yīng)功能障礙的表現(xiàn)  ，此時細(xì)胞功 能并不升高。在急性細(xì)胞損傷時（大多為中毒或缺  氧），線粒體 的嵴被破壞；慢性亞致死性細(xì)胞損傷或營養(yǎng)缺乏時  ，線粒體的蛋 白合成受障，以致線粒體幾乎不再能形成新的嵴。  根據(jù)細(xì)胞損傷 的種類和性質(zhì)，可在線粒體基質(zhì)或嵴內(nèi)形成病理性  包含物。這些 包含物有的呈晶形或副晶形（可能由蛋白構(gòu)成），  如在線粒體性 肌病或進(jìn)行性肌營養(yǎng)不良時所見,有的呈無定形的電  子致密物， 常見于細(xì)胞趨于壞死時，乃線粒體成分崩解的產(chǎn)物（  脂質(zhì)和蛋白 質(zhì)），被視為線粒體不可復(fù)性損傷的表現(xiàn)。
However, mild enlargement may sometimes be an indication of increased function, and more pronounced swelling may be indicative of cell damage. However, as long as the injury, but the role of the injury factor is too long, swelling can still be restored. The increase in mitochondria is sometimes due to adaptive hypertrophy caused by an increase in organ function load, and the number of mitochondria often increases, for example, in the case of organ hypertrophy. On the contrary, when the organs shrink, the mitochondria shrink and become less. Structural changes Mitochondrial quinones are clear indications of energy metabolism, but the increase in cesium is not necessarily accompanied by an increase in respiratory chain enzymes. The parallel increase of membranes and enzymes in the earthworms reflects the increase in the functional load of the cells, which is a manifestation of an adaptive state; conversely, if the increase in the number of membranes and enzymes is not parallel, it is the performance of cytoplasmic adaptation dysfunction, and at this time the cell functions. Does not increase. In acute cell injury (mostly poisoning or hypoxia), mitochondrial defects are destroyed; in the case of chronic sublethal cell damage or nutritional deficiencies, mitochondrial protein synthesis is impaired, so that mitochondria are almost no longer able to form new defects. Depending on the type and nature of cell damage, pathological inclusions can form within the mitochondrial matrix or enamel. These include crystalline or paracrystalline forms (possibly composed of proteins), such as those seen in mitochondrial myopathy or progressive muscular dystrophy, and some are amorphous electron-dense materials that are common when cells tend to become necrotic The product of disintegration of mitochondrial components (lipids and proteins) is considered to be a manifestation of mitochondrial irreversible damage.